1. Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.

    Acta Neuropsychiatrica 27(4):228 (2015) PMID 25858023

    The N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine, produces rapid and enduring antidepressant effect in patients with treatment-resistant depression. Similar dramatic effects have not been observed in clinical trials with other NMDAR antagonists indicating ketamine may possess unique...
  2. Trends in opioid analgesic abuse and mortality in the United States.

    New England Journal of Medicine 372(16):1572 (2015) PMID 25875269

  3. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.

    Psychopharmacology 232(6):1025 (2015) PMID 25260339 PMCID PMC4336651

    In addition to the negative and positive symptoms of schizophrenia, cognitive deficits, including prefrontal cortical dysfunction, are now recognized as core features of this disorder. Compounds increasing the NMDA receptor function via the strychnine-insensitive glycine receptors have been prop...
  4. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.

    Psychopharmacology 232(6):1025 (2015) PMID 25260339

    In addition to the negative and positive symptoms of schizophrenia, cognitive deficits, including prefrontal cortical dysfunction, are now recognized as core features of this disorder. Compounds increasing the NMDA receptor function via the strychnine-insensitive glycine receptors have been prop...
  5. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.

    Psychopharmacology 232(6):1025 (2015) PMID 25260339 PMCID PMC4336651

    In addition to the negative and positive symptoms of schizophrenia, cognitive deficits, including prefrontal cortical dysfunction, are now recognized as core features of this disorder. Compounds increasing the NMDA receptor function via the strychnine-insensitive glycine receptors have been prop...
  6. Synopsis of Expert Opinions and Conclusions.

    CNS and Neurological Disorders 14(6):773 (2015) PMID 26073938

  7. Editorial: Emerging Targets for Stimulant Use Disorders: Where To Invest In An Era Of Constrained Resources?

    CNS and Neurological Disorders 14(6):691 (2015) PMID 26073937

  8. Harry L June.

    PMID 25381711 PMCID PMC4229593

  9. Harry L June.

    PMID 25381711 PMCID PMC4229593

  10. Translational potential of naloxone and naltrexone as TLR4 antagonists.

    Trends in Pharmacological Sciences 35(9):431 (2014) PMID 25109569

  11. Therapeutic doses of buspirone block D3 receptors in the living primate brain.

    International Journal of Neuropsychopharmacology 17(8):1257 (2014) PMID 24679922

    Dopamine D3 receptor (D3R) antagonists may be effective medications for multiple substance use disorders (SUDs). However, no selective D3R antagonists are currently available for clinical testing. Buspirone, originally characterized as a 5-HT1A partial agonist and used as an anxiolytic, also bin...
  12. Therapeutic doses of buspirone block D3 receptors in the living primate brain.

    International Journal of Neuropsychopharmacology 17(8):1257 (2014) PMID 24679922

    Dopamine D3 receptor (D3R) antagonists may be effective medications for multiple substance use disorders (SUDs). However, no selective D3R antagonists are currently available for clinical testing. Buspirone, originally characterized as a 5-HT1A partial agonist and used as an anxiolytic, also bin...
  13. Glutamate-Based Antidepressants: Preclinical Psychopharmacology

    Biological Psychiatry 73(12):1125 (2013)

    Over the past 20 years, converging lines of evidence have both linked glutamatergic dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic synapse presents multiple targets for developing novel antidepressants. The robust antidepressant effects of the ...
  14. Glutamate-based antidepressants: preclinical psychopharmacology.

    Biological Psychiatry 73(12):1125 (2013) PMID 23453290

    Over the past 20 years, converging lines of evidence have both linked glutamatergic dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic synapse presents multiple targets for developing novel antidepressants. The robust antidepressant effects of the N-methyl-D...
  15. Glutamate-based antidepressants: preclinical psychopharmacology.

    Biological Psychiatry 73(12):1125 (2013) PMID 23453290

    Over the past 20 years, converging lines of evidence have both linked glutamatergic dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic synapse presents multiple targets for developing novel antidepressants. The robust antidepressant effects of the N-methyl-D...
  16. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

    International Journal of Neuropsychopharmacology 16(2):445 (2013) PMID 22827916

    Converging lines of evidence indicate that elevations in synaptic dopamine levels play a pivotal role in the reinforcing effects of cocaine, which are associated with its abuse liability. This evidence has led to the exploration of dopamine receptor blockers as pharmacotherapy for cocaine addict...
  17. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

    International Journal of Neuropsychopharmacology 16(2):445 (2013) PMID 22827916

    Converging lines of evidence indicate that elevations in synaptic dopamine levels play a pivotal role in the reinforcing effects of cocaine, which are associated with its abuse liability. This evidence has led to the exploration of dopamine receptor blockers as pharmacotherapy for cocaine addict...
  18. Response to W. Sieghart.

    Trends in Pharmacological Sciences 34(3):146 (2013) PMID 23384390

  19. Response to W. Sieghart

    Trends in Pharmacological Sciences 34(3):146 (2013)

  20. Addiction therapeutics: obstacles and opportunities.

    Biological Psychiatry 72(11):890 (2012) PMID 23121867